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Intestinal antigen encounter leads to recirculation of antigen-specific plasmablasts via lymphatics and blood back to the intestine.
Investigating these gut-originating cells in blood provides a less invasive tool for studying intestinal immune responses, with the
limitation that the cells disappear from the circulation in two weeks. No data exist on situations where pathogens persist in the
intestine. Patients with Salmonella, Yersinia, orCampylobacter gastroenteritis and volunteers receiving an oral typhoid vaccine were
assayed for plasmablasts specific to each subject’s own pathogen/antigen weekly until the response faded. In vaccinees, plasmablasts
disappeared in two weeks. In gastroenteritis, the response faded 2-3 and 3–7 weeks after the last positive Salmonella or Yersinia
stool culture. Even in symptomless patients, pathogens persisting in the intestine keep seeding plasmablasts into the circulation.
Assaying these cells might oﬀer a powerful tool for research into diseases in which persistingmicrobes have a potential pathogenetic
significance.
1. Introduction
The intestine represents the largest immunological tissue
in the body and carries the majority of all lymphocytes
[1, 2]. Pathogens encountered in the intestine activate
antigen-specific lymphocytes in Peyer’s patches, and these
cells migrate to mesenteric lymph nodes and further via
lymphatics and blood to the intestinal lamina propria as
eﬀector lymphocytes [2–6]. Consistent with this recircu-
lation of activated intestinal lymphocytes, antigen-specific
eﬀector lymphocytes have been found in the circulation after
intestinal antigen encounter both after oral [7–11] and rectal
[10, 12] vaccinations and in intestinal infections [13–15].
The mechanisms underlying this recirculation of acti-
vated intestinal lymphocytes have been a subject of extensive
research. It has been shown that dendritic cells in the
intestine present the antigens to lymphocytes in Peyer’s
patches and program these cells to express a set of receptors
determining their later migratory behavior [2–6]. Next, these
activated lymphocytes migrate to mesenteric lymph nodes
and return to the mucosal sites with the help of lymphatics
and blood. This return once appeared to occur randomly
with circulating blood, but, in fact, it exhibits marked
tissue selectivity at the final stage of homing from blood
through the endothelium into the tissues. This homing is
a multistep process requiring an interaction of lymphocyte
surface molecules recognizing their ligands distributed in
a tissue-specific manner in the body [2–6]. Lymphocytes
homing to the intestine express both CCR9 [1–3, 16], a
chemokine receptor mediating homing to the small intestine,
and α4β7 [1–3, 17], a gut-specific homing receptor (HR)
that recognizes Mad-CAM1 on the endothelial venules
of the intestine. The majority of gut-originating antigen-
specific plasmablasts found in the peripheral blood after oral
vaccination [9–11] or in intestinal infections [14] have been
shown to express the gut HR, α4β7, implying a preferential
homing of these cells to the intestinal lamina propria.
Research into intestinal immune responses in the human
gut has been hampered by the instability of antibodies
in secretions and, to an even greater extent, by ethical
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restrictions. Investigation of gut-originating plasmablasts in
the peripheral blood circumvents some of these problems.
Plasmablasts (preplasma cells) are close to end-stage cells
of the B-cell lineage representing only a minor part of all
circulating B cells: recently activated and developed into
eﬀector cells, they constitute the part that actively secretes
antibodies while being on their way to settling down in
the target tissues as plasma cells. Plasmablasts recently
activated in the intestine are identified in the circulation as
antibody-secreting cells (ASCs) with a spontaneous secretion
of antibodies against intestinally encountered antigens [7–
15]. Studies with oral vaccines have shown that these cells
can be caught from the peripheral blood 3–5 days after the
original antigen encounter, they peak in number around day
7 and disappear within two weeks [7, 8, 18], consistent with
their homing back to the mucosa. Catching gut-originating
eﬀector lymphocytes from the circulation has proved a useful
tool in studying mucosal immune responses to both oral
vaccines [7–11] and intestinal infections [13–15]. However,
a major restriction to this approach is the transient nature
of the response: the actual window for catching the cells is
no longer than a few days. The kinetics has been explored
with oral vaccinations [7, 8, 18] where the exact time of
antigen encounter is known and the vaccine antigen persists
in the intestine for only a short time. The present study
investigates the response in natural infections where the
pathogen persists in the intestinal milieu for a longer period
of time. This is of interest also in view of diseases in which
pathogen persistence plays a role in the pathogenesis of the
disease.
2. Methods
Patients with diarrhea and volunteers receiving an oral
typhoid vaccine were studied for circulating plasmablasts
specific to the pathogen isolated from their own stool sample
or to the vaccine antigen, respectively. The kinetics of the
response was studied along with determinations of isotypes.
In order to confirm the intestinal homing commitment of
these migrating cells, the homing profile was determined in
a subgroup of volunteers in both groups.
2.1. Patients. 23 patients attending the Central Hospital of
Central Finland or the Helsinki University Central Hospital
and six healthy volunteers were enrolled in the study.
Informed consent was obtained from each patient/volunteer
before participation. The study was conducted according to
the principles stated in the Helsinki Declaration on human
experimentation, and the study protocol was reviewed and
approved by the Ethics Committees of the participating
hospitals.
22 patients (12 women, 10 men, aged 36–63 years) had
bacterial diarrhea, diagnosed on the basis of watery stools
and a pathogen isolated from stool samples. One patient
had no diarrhea but was examined because of her spouse’s
positive Salmonella culture: her stool culture proved positive
for the same pathogen. In her case, the day of the first positive
stool sample was defined as day 0, while, for all others,
day 0 indicates the day of the first symptoms. None of the
patients had a known previous history of diarrhea caused
by a bacterial pathogen, nor had they been diagnosed with
immune deficiencies or other significant underlying diseases.
Six healthy volunteers (all women, aged 24–47), who had not
received the typhoid vaccination previously, were each given
the oral Salmonella typhi Ty21a vaccine (Vivotif, Crucell,
Switzerland) in three doses two days apart, according to the
manufacturer’s instructions. For vaccinees, the day of the
first vaccine dose was marked as day 0.
2.2. Collection of Blood Samples, Isolation of PBMC, and
Preparation of Antigen. For patients with diarrhea, first
blood samples for ASC analyses were drawn 6–33 days
after the onset of the symptoms, and, for vaccinees, a series
of blood samples was drawn 0, 5, 7, 9, 12, 14, and 16
days after the oral typhoid vaccination and then, in both
groups, weekly for as long as the ASCs were detected or the
pathogen could be recovered from the stool samples, and
the patient was available. Mononuclear cells were isolated
from heparinized blood by Ficoll-Paque density-gradient
centrifugation as described previously [8] and adjusted to
a concentration of 2 × 106 cells/mL. HR expressions were
determined in the first blood sample drawn in five patients
with diarrhea and on day seven after vaccination in five
vaccinees.
Bacterial strains identified in the stool samples were
grown on nutrient agar plates and formalin-killed as
described previously [13, 14, 19, 20]. The concentration of
the bacterial suspension was adjusted to 108 bacteria/mL.
2.3. Separation of Receptor-Negative and Receptor-Positive
Cell Populations. The separation of the cells into receptor-
negative and receptor-positive populations has been
described earlier [9, 14, 21]. Briefly, the cells were
incubated with the monoclonal antibodies anti-α4β7
(ACT-1) (Millennium Pharmaceuticals, Cambridge, MA),
anti-L-selectin (Leu8) (Becton-Dickinson), or anti-CLA
(HECA-452) (received from Dr. Sirpa Jalkanen, University
of Turku, Finland), washed twice, and incubated with
Dynal M-450 magnetic beads coated with sheep anti-mouse
IgG (Dynal, Oslo). The beads with the attached cells were
separated from the suspension by applying a magnet outside
the test tubes and the supernatants with the receptor-
negative cells collected. The receptor-positive cells attached
to the beads were collected. Both the receptor-positive
and receptor-negative cell populations were immediately
analyzed with the enzyme-linked immunospot (ELISPOT)
assay for numbers of ASC.
The eﬃciency of the cell separations was checked in pilot
experiments as described previously [9, 14].
2.4. Assay of Specific Antibody-Secreting Cells. The total
population of PBMC and the receptor-positive and receptor-
negative cell populations were each assayed for specific
ASC with ELISPOT: the assay of specific ASC has been
described previously [8, 13, 14, 19, 20]. In brief, for patients
with diarrhea, 96-well microtiter plates (Maxisorp, Nunc.
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Denmark) were coated with a whole-cell preparation of
formalin-killed pathogen isolated from the stool sample
of the same patient (see above) or, for vaccinees, with a
preparation formalin-killed Salmonella strain SL2404 carry-
ing the O-antigen 9 and 12 similarly to the vaccine strain
Ty21a. The cells were incubated in the wells, and antibodies
secreted during this time detected with alkaline phosphatase-
conjugated anti-human IgA (Sigma-Aldrich, Mo, USA), IgG
(Sigma-Aldrich), and IgM (SouthernBiotech, Birmingham,
AL, USA) followed by application of substrate (bromo-4-
chloro-3-indolyl phosphate p-toluidine salt; Sigma-Aldrich)
in melted agarose. Specific ASCs were enumerated by
counting the spots in the wells in a light microscope. A
response was defined as >2 specific ASC/106 PBMC in at least
one sample.
2.5. Statistics. The numbers of ASC were calculated as
geometric means ± SEM. The proportions of the receptor-
positive ASC were calculated as follows: % of receptor-
positive cells among ASC = (100 X the number of ASC in
receptor-positive population) ÷ (the sum of the number of
ASC in receptor-positive and receptor-negative populations).
Statistical comparisons were carried out using Student’s t-
test. Results of statistical analyses were considered significant
when P < 0.05.
3. Results
3.1. Pathogens and Symptoms. In patients with gastroen-
teritis, Salmonella enteritidis was grown as a pathogen in
stool culture in 10/23 cases, Yersinia enterocolitica in 7/23,
Campylobacter jejuni in 2/23, and S. stockholm, S. bradford, S.
emek, and S. typhimurium each in one case. In 12/23 patients,
only one positive stool sample was obtained, and the second
one taken 1-2 weeks later was negative. In 11/23 patients, 2–
11 positive stool samples were collected. 12/23 patients had
symptoms during the first sampling, and 10/23 of them until
1–5 weeks after it. In 3/23, patients the symptoms had faded
away one week, and in 8/23 patients in 2–4 weeks before the
first blood sample.
3.2. General Characteristics of the Antigen-Specific Plasmablast
Response. All six volunteers vaccinated with Ty21a showed a
vaccine-antigen-specific ASC response similar to that in our
previous studies [8, 12] (Figure 1).
A response of circulating pathogen-specific plasmablasts
was found in 8/10 patients with Salmonella enteritidis
(Figure 2). In one patient, there was no response despite a
positive stool sample one week before (symptoms started 22
days earlier). In one patient, the blood sample was obtained
only four weeks after the last positive stool sample and last
symptoms. Circulating ASCs were detected in 5/7 patients
with Yersinia enterocolitica (Figure 3). In one patient with
a clear response, no further follow-up samples could be
obtained. No ASCs were found in 2/7 patients: in both
of these cases, the sample was drawn one week after the
symptoms had faded and four weeks after the last positive
stool sample.
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Figure 1: Numbers of vaccine antigen (O9,12)-specific circulating
plasmablasts identified as antibody-secreting cells/106 PBMC (IgA-
+ IgG- + IgM) in six volunteers vaccinated with the live oral
Salmonella typhi Ty21a vaccine. Each volunteer received one vaccine
dose on days 0, 2, and 4 (the vaccination days are indicated with
“+”). To determine the kinetics of the response, the numbers of
plasmablasts were determined on several days for as long as ASCs
were found in the samples. The values of each individual are
connected with a line.
Patients with S. bradford, S. emek, and S. typhimurium as
pathogens had a response (Figures 4(a)–4(c)). The patient
with Salmonella stockholm did not show a response even
though the samples were drawn one week after positive stool
culture and last symptoms. One patient with Campylobacter
jejuni had a vigorous response (10 000ASC/106 PBMC)
(Figure 4(d)), while the other one showed no response; her
blood sample was drawn three weeks after the last positive
stool sample.
Among the vaccinees, IgA-ASC predominated in three
volunteers, IgG in two, and IgM in one. The geometric mean
of the peak of the responses (IgA + IgG + IgM-ASC) was
215 ± 184/106 PBMC. The isotype distribution is shown in
Figure 5.
Out of all patients, the response was dominated by IgA in
15/17 cases and IgM in 2/17 cases (one with S. typhimurium
and one with Yersinia enterocolitica). The geometric mean of
the peak of the responses (IgA + IgG + IgM-ASC) was 64 ±
70/106 PBMC in patients with S. enteritidis and 459±614/106
PBMC with Yersinia enterocolitica. The isotype distributions
are shown in Figure 5.
3.3. Kinetics of the Antigen-Specific Plasmablast Response. In
the vaccinees, the response peaked on day 7 and declined
thereafter. No samples were drawn after day 16, since the
response had faded away/was negligible already on that day
in all volunteers (Figure 1).
In patients with gastroenteritis, the numbers of antigen-
specific ASC were followed weekly for as long as the response
persisted or the stool culture remained positive, and the
patient was available. The highest number of ASC was in
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Figure 2: Relation of pathogen-specific circulating plasmablasts (black curve) with symptoms (black horizontal line) and findings in stool
samples (+ or−) in eight patients with gastroenteritis caused by Salmonella enteritidis. To determine the kinetics of the response, the numbers
of plasmablasts were assessed on several occasions as long as they were found in the samples or the pathogen could be isolated from the stool
samples, and the patient was available. The plots represent each data from one individual. The day of the onset of the symptoms was marked
as day 0.
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Figure 3: Relation of pathogen-specific circulating plasmablasts (black curve) with symptoms (black horizontal line) and findings in stool
samples (+ or −) in four patients with gastroenteritis caused by Yersinia enterocolitica. The plots represent each data from one individual.
The day of the onset of the symptoms was marked as day 0.
12/16 cases found in the first sample drawn, that is, soon after
the beginning of symptoms and after that the magnitude
of the response appeared to fluctuate until it faded away
(Figures 2–4). The numbers of weekly blood samples drawn
varied from one till up to 12 (Figures 2–4). The fading
of ASC appeared to be associated with the stool samples
turning negative, rather than the subsiding of the symptoms,
as the ASC response was prolonged in some volunteers with
persisting positive stool cultures even after the symptoms had
subsided (Figures 2(a), 2(c), 2(f)). The response appeared to
fade away faster after Salmonella (2-3 weeks) (Figure 2) than
after Yersinia infection (3–7 weeks) (Figure 3).
3.4. The Expression of HR on Antigen-Specific Plasmablasts.
The expressions of various HR on ASC specific to the
diarrheal pathogen or the vaccine antigen were studied in
five patients with Salmonella diarrhea and in five vaccinees,
respectively. In the diarrhea group, the proportion α4 β7 +
ASC among all ASC was 94±6%, L-selectin + ASC 46±24%,
and CLA + ASC 4 ± 4%. Among vaccinees, the respective
figures were 97 ± 2%, 24 ± 18%, and 1 ± 2%. These data
did not reveal any statistical diﬀerence in the HR expressions
between diarrhea patients and vaccinees but are consistent
with the intestinal homing profile of the migrating cells in
both groups.
4. Discussion
Investigation of gut-originating plasmablasts from samples
of peripheral blood during their recirculation serves as a
valuable, less invasive tool for studying intestinal immune
response in humans. Instead of examining memory B cells,
this approach centers on gut-directed plasmablasts cells
spontaneously secreting antibodies against antigens they
have encountered recently, that is, the method measures
an ongoing intestinal immune response. The transient
appearance of these cells in the circulation, which allows only
a few days for actual sampling, has posed a severe limitation
to this approach. The present study is the first to focus on the
kinetics of this response during a natural infection in which
the pathogen can persist in the intestine for a longer period
of time. It shows that the previously presumed kinetics does
6 Clinical and Developmental Immunology
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Figure 4: Relation of pathogen-specific circulating plasmablasts (black curve) with symptoms (black horizontal line) and findings in
stool samples (+ or −) in four patients with gastroenteritis caused by (a) Salmonella typhimurium, (b) S. emek, (c) S. bradburg, and (d)
Campylobacter jejuni. The plots represent each data from one individual. The day of the onset of the symptoms was marked as day 0.
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Figure 5: The isotype distribution in the peak of the specific
plasmablast response in volunteers vaccinated with the oral live
Salmonella typhi Ty21a vaccine (n = 6) and in patients with
gastroenteritis caused by Salmonella enteritidis (n = 8) or Yersinia
enterocolitica (n = 5). The data are given as geometric means of
ASC /106 PBMC ± SEM.
not apply to natural infections: if the pathogens persist in
the intestine, the actual time frame for sampling can be
significantly extended.
4.1. Comparison to Serum Antibody Responses. Assessment
of plasmablasts has significant advantages as compared
to serum antibody assays. Firstly, plasmablast response
measures an immune response to antigens encountered
recently, whereas serum antibodies may remain elevated
throughout life even if the antigen was encountered decades
ago [22]. Secondly, plasmablast assay allows an assessment
of the response to each individual’s own pathogen. Thirdly,
plasmablast response has proved significantly more sensitive
than serum antibodies when measuring humoral immune
response to intestinal antigen encounter [8]. Our previous
studies have shown that shortly after oral vaccination, when
antibodies are presumed to exist in intestinal secretions,
serum antibodies even fail to rise at all upon intesti-
nal antigen encounter, despite a simultaneous significant
plasmablast response [23]. This describes the independent
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nature of systemic and mucosal immune systems and further
stresses the role of plasmablast instead of serum antibody
measurements when assessing intestinal immune responses:
plasmablasts represent intestinal immune response, whereas
serum antibodies are mainly produced in the bone marrow.
Serum antibodies remaining fairly constant for long periods
of time do not provide any information as to whether the
pathogen persists in the intestine or the pathogen has been
cleared. Up until now, it has been assumed that exploring
plasmablasts would not provide such information either, as
the cells were thought to be found in the circulation for
two weeks only. The continued recruitment of plasmablasts
in the present study suggests that the use of the assay of
specific plasmablasts can be extended and even applied to the
evaluation of antigen persistence in the intestine.
4.2. Significance of the Continuous Recruitment of Plas-
mablasts. Continuous recruitment of plasmablasts appears
to be a means of enhancing the immune response to a
pathogen the body has not succeeded in expelling. The gen-
erally lower numbers of plasmablasts recruited as the time
passes and the even negligible numbers seen occasionally
in the later course of the response may be a reflection of
antibody responses in the intestine already working against
the pathogens. However, such fluctuations in the magnitude
of the response with occasional negligible numbers of
plasmablasts strongly suggest that a single negative sample
does not indicate that the pathogen no longer persists, and
therefore, multiple sampling may be required. The highest
numbers of plasmablasts are found early in the course of
the response. Previous to this we have, in fact, shown that
if an oral vaccine is given in six instead of three doses, the
plasmablast response is prolonged till day 22, and even if no
clear peak can be seen, the response is at its highest on day 7
[24]. The early peak in the response means that (possible)
comparisons in response magnitude between two groups
should be carried out on the basis of samples drawn at early
stages of the disease, while, in other samples, a qualitative
comparison is mainly feasible. It would be interesting to see
if chronic carriers of intestinal pathogens (e.g., Salmonella)
still have an ongoing recruitment of plasmablasts, as the
pathogen can in such cases be regarded to have become part
of their regular intestinal microbiota. As to the disappearance
of ASC, it is not possible to draw any definite conclusions.
In the present data, however, the response seemed to fade
away faster after Salmonella (2-3 weeks; Figures 2 and 4) than
after Yersinia infection (3–7 weeks; Figure 3). As opposed to
infections with real multiplying pathogens, the Ty21a vaccine
strain is supposed to survive in the intestine only for one
or two days. Accordingly, data comparing responses after
three versus six doses of Ty21a [24] suggest that in cases with
nonreplicating antigens, the plasmablasts disappear from the
circulation approximately 8–10 days after the last day of
antigen encounter.
Notably, even if the present study focuses on plasmablast
response after intestinal antigen encounter, a recirculation of
antigen-specific plasmablasts also occurs after nonintestinal
encounter [9, 25–27], for example, in infections at other
mucosal sites [10, 19, 20, 28] and after parenteral vaccina-
tions [9, 14, 25–27, 29, 30]. As evidenced by their HR profiles,
these plasmablasts are traﬃcking to nonintestinal sites. Thus,
it appears that assaying these cells could be applied to assess
persistence of pathogens at nonintestinal sites, too.
5. Conclusion
In conclusion, the recruitment of pathogen-specific plas-
mablasts in the circulation in gastroenteritis has proved
less transient than previously reported. Instead, the recruit-
ment seems to continue as the pathogen persists in the
intestine, albeit at a lower or, occasionally, even negligible
level, indicating that repeated sampling may be necessary.
Continued recruitment of plasmablasts in the circulation not
only reflects a continuous stimulation of the immune system
but also carries potential for assessing immune response to
persisting antigens that are suspected to be of significance in
the pathogenesis of a disease.
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ASC: Antibody-secreting cell
CCR: Chemokine receptor
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